散发性CJD患者新的潜在标志物H-FABP的检测  

Detection of H-FABP as a new potential marker for the diagnosis of sporadic Creutzfeldt-Jakob Disease

作　　者：左秀美[1] 王东升[2] 赵节绪[1] 樊丽超[1] 南善姬[1] 

机构地区：[1]吉林大学第一医院神经内科,吉林长春130021 [2]吉林大学朝阳校区医院,吉林长春130021

出　　处：《中风与神经疾病杂志》2006年第2期181-182,共2页Journal of Apoplexy and Nervous Diseases

基　　金：国家自然科学基金(30070266)

摘　　要：目的通过检测散发性CJD患者血清和脑脊液中心脏型脂肪酸结合蛋白(H—FABP)的含量,来探索 H—FABP对于CJD生前诊断的意义。方法应用ELISA方法对我科1998年～2005年收集的散发性CJD患者血清 13例和脑脊液17例进行H—FABP检测,同时设立正常对照组,进行统计学分析。结果散发性CJD患者血清及脑脊液H—FABP浓度均较正常对照组高,具有统计学意义。结论作为散发性CJD新的潜在生物学标志物H—FABP 的检测结果有助于该病的生前诊断,进行血液筛查也能降低CJD通过输血进行医源性传播的危险性。Objective To research the significance of H-FABP for the pre-mortem diagnosis of sporadic Creutzfeldt-Jakob Disease（CJD） during detecting the amount of H-FABP in cerebrospinal fluid （CSF） and serum of sporadic CJD patients. Methods We measured H-FABP in cerebrospinal fluid （CSF） and serum of sporadic CJD patients collected in our department from 1998 to 2005. A control group was set up simultaneously and the statistical analysis was taken. Results The amount of H-FABP in cerebrospinal fluid （CSF） and serum of sporadic CJD patients was significantly higher than that in the control group（P〈0.05）. Conclusions The detection of H-FABP as a new potential biomarker of sporadic CJD could therefore be helpful for a pre-mortem diagnosis of the disease and applying a blood screening test may prevent the risk of iatrogenic transmission of CJD through blood transfusion.

关 键 词：克-雅氏病 检测 心脏型脂肪酸结合蛋白 

分 类 号：R742[医药卫生—神经病学与精神病学]